INVESTOR ALERT: The Inspire Medical Systems, Inc. Securities Fraud Class Action is Pending, Investors Urged to Contact BFA Law by January 5 DeadlineDecember 04, 2025 3:46 PM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - December 4, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) and certain of the Company's senior executives for securities fraud aft ...

NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Inspire Medical Systems, Inc. (NYSE: INSP). Shareholders who purchased shares of INSP during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/inspire-medical-systems-inc-loss-submission-form/?id=179479&from=3  CL ...

INSPIRE STOCK ALERT: Inspire Medical Systems, Inc. (INSP) Investors Reminded to Contact BFA Law Prior to the January 5 Deadline in Securities Fraud Class ActionDecember 03, 2025 3:36 PM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - December 3, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) and certain of the Company's senior executives for securiti ...

Partner Reed Kathrein ScrutinizingAllegedConcealment of Billing Code Errors and Inventory Glut Driving 80% Guidance CutSAN FRANCISCO,Dec. 3, 2025/PRNewswire/ -- National shareholder rights law firm**Hagens Berman**reminds investors that the deadline to move the Court for appointment as lead plaintiff in the securities class action lawsuit against**Inspire Medical Systems, Inc. (NYSE:[INSP](#financial- modal))**is**January 5, 2026.**The lawsuitallegesthat Inspire Medical and its executives misled investors b ...

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and its senior executives for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Minnesota, specifically titled City of Pontiac Reestablished General Employees' Retirement System v. Inspire Medical Systems, Inc., et al., No. 0:25-cv-04247 [3]. - Investors have until January 5, 2026, to request to lead the case, with claims made under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. Group 2: Company Background - Inspire Medical Systems develops and manufactures an implantable medical device for treating sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Group 3: Stock Performance and Issues - Inspire Medical Systems assured investors that it had taken necessary steps for the launch of Inspire V, claiming high demand would support the rollout [5]. - Contrary to these assurances, the company allegedly failed to prepare clinicians and payors adequately, leading to significant delays and weak demand due to excess inventory of older devices [6]. - On August 4, 2025, Inspire disclosed an "elongated timeframe" for the Inspire V launch and reduced its 2025 earnings per share guidance by over 80%, attributing this to undisclosed factors including incomplete training at implanting centers and poor demand [7]. - Following this announcement, Inspire's stock price fell by $42.04 per share, a decline of more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].

LOS ANGELES--(BUSINESS WIRE)--Inspire Medical Systems, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – INSP. ...

SAN FRANCISCO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman reminds investors that the deadline to move the Court for appointment as lead plaintiff in the securities class action lawsuit against Inspire Medical Systems, Inc. (NYSE: INSP) is January 5, 2026. The lawsuit alleges that Inspire Medical and its executives misled investors by providing assurances of “operational readiness” for the Inspire V device launch, while concealing critical failures in billing softwar ...

INSP COURT ALERT: Inspire Medical Systems, Inc. Investors are Notified the Company has been Sued for Securities Fraud and are Notified to Contact BFA Law by January 5December 02, 2025 3:33 PM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - December 2, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) and certain of the Company's senior executives for se ...

PresentationAdam MaederPiper Sandler & Co., Research Division All right. We're live here, so we're going to get going. Welcome to the 2025 Piper Sandler Healthcare Conference. My name is Adam Maeder. I'm one of the Med Tech analyst here at Piper. Very pleased to introduce the team from Inspire Medical. With us, we have Tim Herbert, Chairman and CEO; and Ezgi Yagci, from Investor Relations. Thanks so much for joining us. ...

Inspire Medical Systems FY Conference Summary Company Overview - **Company**: Inspire Medical Systems (NYSE: INSP) - **Industry**: Medical Devices, specifically focused on sleep apnea treatment Key Points Q4 Guidance and Business Visibility - The company expressed confidence in achieving Q4 implied guidance following a strong Q3 performance, which included beating revenue and EPS expectations. The full-year revenue guidance for 2025 was reaffirmed, indicating a significant quarter-over-quarter revenue increase is expected [1][2][3] Product Transition and Inventory Management - The transition from Inspire 4 to Inspire 5 has been successful, with over 75% of U.S. accounts performing Gen 5 procedures. The company expects to complete the transition by year-end, with minimal inventory impact moving forward [5][6][8] - The company noted that December is typically the busiest month for implants due to high-deductible insurance plans, which is expected to drive Q4 performance [3] Reimbursement Changes - A significant reimbursement change for CPT code 64568 is anticipated for 2026, with a 40-50% year-over-year increase in facility reimbursement, which is expected to positively impact the business [12][13] - The new tech APC is seen as a bridge to potentially achieving a level 6 APC in the future, which would further enhance reimbursement rates [15] Growth Projections - The company provided an early indication of a 10-11% top-line growth for 2026, although this is not formal guidance. The focus will be on consistency and establishing a starting point for future expectations [9][10] Patient Warehousing and Utilization - The issue of patient warehousing, where patients delayed treatment for the new Inspire 5 device, has largely been resolved, with most patients now in the queue for treatment [7][8] - Centers that have fully transitioned to Inspire 5 are experiencing over 20% year-over-year volume increases, indicating strong acceptance and utilization of the new device [18][19] Competitive Landscape - The company acknowledged the emergence of a second competitor in the market but emphasized the established safety and efficacy of Inspire's products. New data showing improved health outcomes for Inspire over CPAP is expected to strengthen its market position [31][32][33] Replacement Device Opportunity - The reimbursement for replacement devices has improved, with expectations of a high replacement rate of up to 80% for patients receiving therapy. The battery life of devices is approximately 10-11 years, leading to a new revenue stream as older devices are replaced [26][27] Impact of GLP-1 Medications - The company noted that GLP-1 medications are increasing the diagnosis rate of obstructive sleep apnea, which could lead to a favorable tailwind for Inspire as more patients seek treatment [28][29][30] Financial Outlook - The transition to Inspire 5 is expected to positively impact gross margins due to the elimination of the expensive pressure-sensing lead. Operating margins are anticipated to increase as the company continues to support direct-to-consumer initiatives [34] Leadership Transition - The company is in the process of searching for a new CFO, with several candidates being interviewed. An announcement regarding the new hire is expected soon [35] Future Developments - Inspire is working on a dual-channel device to address both tongue-based and lateral wall collapse in obstructive sleep apnea patients, which could expand its treatment capabilities [36] Conclusion Inspire Medical Systems is positioned for growth with the successful launch of Inspire 5, favorable reimbursement changes, and an increasing patient base due to the impact of GLP-1 medications. The company is focused on enhancing its market position while navigating competitive dynamics and preparing for future leadership transitions.